Vaxcyte, Inc. (PCVX): Among Hedge Funds' Top Biotech Stock Picks
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Vaxcyte Is Maintained at Outperform by Mizuho
Vaxcyte Analyst Ratings
Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
Mizuho Securities analyst Salim Syed maintains $Vaxcyte(PCVX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 39.4% and a total average return of -6.2% over the
Vaxcyte's VAX-31 Vaccine: A Strong Buy With Increased Revenue Projections and Substantial Market Potential
Express News | Vaxcyte Inc : Mizuho Raises Target Price to $163 From $113
Vaxcyte's Stock Down 3% After Biotech Unveils Share Sale
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating
TD Cowen analyst Tara Bancroft maintains $Vaxcyte(PCVX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 55.4% and a total average return of 17.7% over the past
Vaxcyte: BofA Securities, Jefferies Among Managers for Offering >PCVX
Vaxcyte Has Granted Underwriters Option for Additional 1,893,203 Shares >PCVX
Vaxcyte Offering Is Expected to Close on September 6 >PCVX
Vaxcyte Shares Being Sold at $103.00 Each >PCVX
Express News | Vaxcyte Inc - Pre-Funded Warrants Are Being Sold at a Public Offering Price of $102.999 per Pre-Funded Warrant.
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
Press Release: Vaxcyte Announces Pricing of $1.3 Billion Public Offering
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $130
Guggenheim analyst Seamus Fernandez maintains $Vaxcyte(PCVX.US)$ with a buy rating, and adjusts the target price from $65 to $130.According to TipRanks data, the analyst has a success rate of 61.1%
A Quick Look at Today's Ratings for Vaxcyte(PCVX.US), With a Forecast Between $113 to $160
On Sep 04, major Wall Street analysts update their ratings for $Vaxcyte(PCVX.US)$, with price targets ranging from $113 to $160.BofA Securities analyst Jason Gerberry maintains with a buy rating,
Vaxcyte Is Maintained at Buy by B of A Securities